Acadia Healthcare's 
ACHC stock has fallen nearly -76% in a year, primarily due to weak 2024 results, missed revenue and EPS expectations, and a soft 2025 revenue guidance. Ongoing federal investigations into billing practices and lawsuits have further eroded investor confidence. However, it is currently trading at a price-to-earnings ratio of 7.42x and earnings are forecast to grow 7.07% per year. The profitable company is trading at a good value compared to other healthcare companies. Debt-to-equity is relatively low (0.64x), but legal risks (DOJ probe, lawsuits) strain margins.
The stock has entered my "major crash" simple moving average territory and there is a lot of downward / selling pressure. But, more often than not, this area (which... I caution... still extends down near $16) can often signal a temporary or longer-term bottom. Personally, this is a buy area ($16-$21) even if it turns into a short-term bounce in 2025. But I believe the overall market moves in the S&P 500, etc. will guide this stock more than anything at this point (unless more bad news about the company emerges).
One thing to note is that there are open price gaps on the daily chart near $17, $10, and $8. These gaps, which often (but not always) get closed in the lifetime of a stock, are a potential signal for further declines - at least at some point. There could be a drop near $16, then a $10-$20 bullish price increase after that, followed by more declines (trapping investors). Time will tell, butACHC is currently attractively valued. From a technical analysis standpoint, it is in a personal "buy zone", even if purely for a swing trade.
Targets:
ACHC stock has fallen nearly -76% in a year, primarily due to weak 2024 results, missed revenue and EPS expectations, and a soft 2025 revenue guidance. Ongoing federal investigations into billing practices and lawsuits have further eroded investor confidence. However, it is currently trading at a price-to-earnings ratio of 7.42x and earnings are forecast to grow 7.07% per year. The profitable company is trading at a good value compared to other healthcare companies. Debt-to-equity is relatively low (0.64x), but legal risks (DOJ probe, lawsuits) strain margins.The stock has entered my "major crash" simple moving average territory and there is a lot of downward / selling pressure. But, more often than not, this area (which... I caution... still extends down near $16) can often signal a temporary or longer-term bottom. Personally, this is a buy area ($16-$21) even if it turns into a short-term bounce in 2025. But I believe the overall market moves in the S&P 500, etc. will guide this stock more than anything at this point (unless more bad news about the company emerges).
One thing to note is that there are open price gaps on the daily chart near $17, $10, and $8. These gaps, which often (but not always) get closed in the lifetime of a stock, are a potential signal for further declines - at least at some point. There could be a drop near $16, then a $10-$20 bullish price increase after that, followed by more declines (trapping investors). Time will tell, but
ACHC is currently attractively valued. From a technical analysis standpoint, it is in a personal "buy zone", even if purely for a swing trade. Targets:
- $27.00
- $33.00
- $39.00
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.